VeraBank N.A. Sells 684 Shares of Pfizer Inc. (NYSE:PFE)

VeraBank N.A. trimmed its holdings in Pfizer Inc. (NYSE:PFEFree Report) by 1.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,023 shares of the biopharmaceutical company’s stock after selling 684 shares during the quarter. VeraBank N.A.’s holdings in Pfizer were worth $1,055,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PFE. Gold Investment Management Ltd. increased its position in Pfizer by 16.3% in the first quarter. Gold Investment Management Ltd. now owns 53,596 shares of the biopharmaceutical company’s stock worth $1,487,000 after purchasing an additional 7,526 shares during the period. TFB Advisors LLC acquired a new stake in Pfizer in the first quarter worth about $358,000. Mediolanum International Funds Ltd acquired a new stake in Pfizer in the first quarter worth about $7,078,000. Pzena Investment Management LLC increased its position in Pfizer by 181.6% in the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock worth $212,855,000 after purchasing an additional 4,947,000 shares during the period. Finally, Larson Financial Group LLC increased its position in Pfizer by 49.0% in the first quarter. Larson Financial Group LLC now owns 33,769 shares of the biopharmaceutical company’s stock worth $937,000 after purchasing an additional 11,101 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 2.3 %

NYSE PFE traded up $0.63 during trading on Wednesday, hitting $28.35. The stock had a trading volume of 26,990,295 shares, compared to its average volume of 40,022,254. The company has a market capitalization of $160.65 billion, a PE ratio of -472.42, a P/E/G ratio of 1.10 and a beta of 0.69. The company’s 50-day moving average price is $28.21 and its two-hundred day moving average price is $27.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the business posted $1.23 EPS. The business’s revenue was down 19.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.93%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $35.54.

View Our Latest Stock Report on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.